Research Article
Adjuvant Iodine131 Lipiodol after Resection of Hepatocellular Carcinoma
Table 2
Treatment details.
| | Surgery only | Surgery + I131-lipiodol | Significance ( value) |
| Dose of I131 lipiodol (GBq) | — | 1.8 | | Liver resection, | | | 0.56 | Major | 22 | 21 | | Minor | 30 | 37 | | Deaths, | 25 | 20 | 0.16 | Recurrences, | 34 | 38 | | Intrahepatic | 29 | 33 | 1.0 | Lung | 3 | 3 | 1.0 | Bone | 2 | 1 | 0.60 | Other | 0 | 1 | 1.0 | Treatment of recurrence, | | | | Transarterial chemoembolization (TACE) | 12 | 12 | 0.81 | Repeat liver resection | 4 | 13 | 0.038 | Salvage liver transplant | 4 | 4 | 1.0 | Ablation | 9 | 9 | 0.79 | DC bead TACE | 2 | 3 | 1.0 | Percutaneous ethanol | 6 | 3 | 0.29 | Palliative I131 lipiodol | 1 | 2 | 1.0 | External beam radiotherapy | 0 | 3 | 0.24 | Sorafenib | 3 | 1 | 0.005 | Systemic chemotherapy | 3 | 0 | Sandostatin | 2 | 0 | Temozolomide | 1 | 0 |
|
|